81 related articles for article (PubMed ID: 26946048)
1. Lymphomagenesis-related gene expression in B cells from sustained virological responders with occult hepatitis C virus infection.
Roque Cuéllar MC; García-Lozano JR; Sánchez B; Praena-Fernández JM; Martínez Sierra C; Núñez-Roldán A; Aguilar-Reina J
J Viral Hepat; 2016 Aug; 23(8):606-13. PubMed ID: 26946048
[TBL] [Abstract][Full Text] [Related]
2. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection.
Castillo I; Bartolomé J; Quiroga JA; Barril G; Carreño V
Aliment Pharmacol Ther; 2009 Sep; 30(5):477-86. PubMed ID: 19523175
[TBL] [Abstract][Full Text] [Related]
3. Activation-induced cytidine deaminase in B cells of hepatits C virus-related cryoglobulinaemic vasculitis.
Russi S; Dammacco F; Sansonno S; Pavone F; Sansonno D
Clin Exp Immunol; 2015 Dec; 182(3):323-31. PubMed ID: 26219420
[TBL] [Abstract][Full Text] [Related]
4. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection.
Hsi E; Huang CF; Dai CY; Juo SH; Chou WW; Huang JF; Yeh ML; Lin ZY; Chen SC; Wang LY; Chuang WL; Yu ML
Antiviral Res; 2014 May; 105():135-42. PubMed ID: 24637254
[TBL] [Abstract][Full Text] [Related]
7. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
[TBL] [Abstract][Full Text] [Related]
8. Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy.
Gelderblom HC; Zaaijer HL; Dijkgraaf MG; Van Der Meer J; Weegink CJ; Jansen PL; Beld MG; Reesink HW
Scand J Gastroenterol; 2008; 43(7):857-69. PubMed ID: 18584525
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients.
Ito M; Murakami K; Suzuki T; Mochida K; Suzuki M; Ikebuchi K; Yamaguchi K; Mizuochi T
Clin Immunol; 2010 Jun; 135(3):459-65. PubMed ID: 20189883
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD81, SR-BI and LDLR in lymphocytes and monocytes from patients with classic and occult hepatitis C virus infection.
Roque-Cuéllar MC; Sánchez B; García-Lozano JR; Garrido-Serrano A; Sayago M; Praena-Fernández JM; Núñez-Roldán A; Aguilar-Reina J
J Med Virol; 2012 Nov; 84(11):1727-36. PubMed ID: 22997075
[TBL] [Abstract][Full Text] [Related]
11. Skewed B cells in chronic hepatitis C virus infection maintain their ability to respond to virus-induced activation.
Oliviero B; Mantovani S; Ludovisi S; Varchetta S; Mele D; Paolucci S; Baldanti F; Mondelli MU
J Viral Hepat; 2015 Apr; 22(4):391-8. PubMed ID: 25258145
[TBL] [Abstract][Full Text] [Related]
12. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
13. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
15. Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles.
Pham TN; Mercer SE; Michalak TI
J Viral Hepat; 2009 Aug; 16(8):547-56. PubMed ID: 19215578
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients.
Baid-Agrawal S; Schindler R; Reinke P; Staedtler A; Rimpler S; Malik B; Frei U; Berg T
J Hepatol; 2014 May; 60(5):928-33. PubMed ID: 24447875
[TBL] [Abstract][Full Text] [Related]
17. Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells.
Zaghloul H; El-Sherbiny W
Immunol Invest; 2010 Jan; 39(3):284-91. PubMed ID: 20380524
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment.
Pham TN; Lin DM; Mulrooney-Cousins PM; Churchill ND; Kowala-Piaskowska A; Mozer-Lisewska I; Machaj A; Pazgan-Simon M; Zalewska M; Simon K; King D; Reddy SB; Michalak TI
J Med Virol; 2013 Mar; 85(3):441-8. PubMed ID: 23280583
[TBL] [Abstract][Full Text] [Related]
19. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
20. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
Sarrazin C; Schwendy S; Möller B; Dikopoulos N; Buggisch P; Encke J; Teuber G; Goeser T; Thimme R; Klinker H; Boecher WO; Schulte-Frohlinde E; Prinzing R; Herrmann E; Zeuzem S; Berg T
Gastroenterology; 2011 Nov; 141(5):1656-64. PubMed ID: 21784046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
